-
'At home' Djokovic makes winning return in Athens
-
Manchester City have become 'more beatable', says Dortmund's Gross
-
Merino brace sends Arsenal past Slavia in Champions League
-
Djokovic makes winning return in Athens
-
Napoli and Eintracht Frankfurt in Champions League stalemate
-
Arsenal's Dowman becomes youngest-ever Champions League player
-
Cheney shaped US like no other VP. Until he didn't.
-
Pakistan edge South Africa in tense ODI finish in Faisalabad
-
Brazil's Lula urges less talk, more action at COP30 climate meet
-
Barca's Lewandowski says his season starting now after injury struggles
-
Burn urges Newcastle to show their ugly side in Bilbao clash
-
French pair released after 3-year Iran jail ordeal
-
EU scrambles to seal climate targets before COP30
-
Getty Images largely loses lawsuit against UK AI firm
-
Cement maker Lafarge on trial in France over jihadist funding
-
Sculpture of Trump strapped to a cross displayed in Switzerland
-
Pakistan's Rauf and Indian skipper Yadav punished over Asia Cup behaviour
-
Libbok welcomes 'healthy' Springboks fly-half competition
-
Reeling from earthquakes, Afghans fear coming winter
-
Ronaldo reveals emotional retirement will come 'soon'
-
Munich's surfers stunned after famed river wave vanishes
-
Iran commemorates storming of US embassy with missile replicas, fake coffins
-
Gauff sweeps Paolini aside to revitalise WTA Finals defence
-
Shein vows to cooperate with France in probe over childlike sex dolls
-
Young leftist Mamdani on track to win NY vote, shaking up US politics
-
US government shutdown ties record for longest in history
-
King Tut's collection displayed for first time at Egypt's grand museum
-
Typhoon flooding kills over 40, strands thousands in central Philippines
-
Trent mural defaced ahead of Liverpool return
-
Sabalenka to face Kyrgios in 'Battle of Sexes' on December 28
-
Experts call for global panel to tackle 'inequality crisis'
-
Backed by Brussels, Zelensky urges Orban to drop veto on EU bid
-
After ECHR ruling, Turkey opposition urges pro-Kurd leader's release
-
Stocks drop as tech rally fades
-
UK far-right activist Robinson cleared of terror offence over phone access
-
World on track to dangerous warming as emissions hit record high: UN
-
Nvidia, Deutsche Telekom unveil 1-bn-euro AI industrial hub
-
Which record? Haaland warns he can get even better
-
Football star David Beckham hails knighthood as 'proudest moment'
-
Laurent Mauvignier wins France's top literary award for family saga
-
Indian Sikh pilgrims enter Pakistan, first major crossing since May conflict
-
Former US vice president Dick Cheney dies at 84
-
Fiorentina sack Pioli after winless start in Serie A
-
Stocks drop as traders assess tech rally
-
Oscar-winning Palestinian films daily 'Israeli impunity' in West Bank
-
Spain's Telefonica shares drop on dividend cut, net loss
-
Fierce mountain storms kill nine in Nepal
-
Divisive Czech cardinal Dominik Duka dies at 82
-
Shein vows to cooperate with France in sex doll probe
-
EU in last-ditch push to seal climate targets before COP30
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
M.Qasim--SF-PST